Core Insights - Pomerantz LLP is investigating claims on behalf of investors of MoonLake Immunotherapeutics regarding potential securities fraud or unlawful business practices [1] - MoonLake reported disappointing results from its Phase 3 VELA trials for sonelokimab, with one trial failing to meet its primary endpoint and the other showing only modest gains compared to placebo [1] - Following the trial results, MoonLake's stock price plummeted by $55.75 per share, a decrease of 89.93%, closing at $6.24 per share on September 29, 2025 [1] Company Overview - MoonLake Immunotherapeutics is a company listed on NASDAQ under the ticker MLTX [1] - The company is involved in the development of immunotherapeutic treatments, specifically focusing on sonelokimab [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [2] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Organogenesis Holdings Inc. following the failure of a key clinical trial for its product ReNu, which has led to a significant drop in the company's stock price [1][2]. Group 1: Company Performance - On September 25, 2025, Organogenesis announced that its second phase 3 trial for the cryopreserved amniotic suspension allograft ReNu did not meet its primary endpoint, failing to show a significant change in pain reduction [1]. - Following this announcement, Organogenesis's stock price decreased by $0.58 per share, or 12.39%, closing at $4.10 per share on September 26, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Organogenesis and its officers/directors regarding possible securities fraud or other illegal business practices [1]. - The firm has a long history in corporate and securities class litigation, having recovered substantial damages for victims of securities fraud and corporate misconduct [3].

Core Points - A class action lawsuit has been filed against Fortinet, Inc. for alleged securities fraud and unlawful business practices [2] - Fortinet disclosed during its earnings call that it was 40% to 50% through the 2026 upgrade cycle for its FortiGate firewalls, indicating challenges in predicting upgrade needs and suggesting customers may not require upgrades due to excess capacity [2] - Following the news, Fortinet's stock price dropped by $21.28, or 22.03%, closing at $75.30 per share [3] Summary by Sections Class Action Details - The lawsuit concerns potential securities fraud by Fortinet and its officers/directors [2] - Investors have until November 21, 2025, to request to be appointed as Lead Plaintiff if they purchased Fortinet securities during the Class Period [2] Company Performance - Fortinet's earnings call revealed that the refresh cycle for FortiGate firewalls had limited business impact, as only a small percentage of the business was affected [2] - The company admitted difficulty in predicting the total number of FortiGates needing upgrades and noted that prior purchases had led to excess firewall capacity [2] Stock Market Reaction - The announcement led to a significant decline in Fortinet's stock price, reflecting investor concerns over the company's future performance and upgrade cycle [3]

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. and certain officers, alleging violations of federal securities laws during the Class Period from July 29, 2024, to January 6, 2025, related to the company's merger with Koito Manufacturing Co., Ltd. [1][5] Group 1: Class Action Details - The lawsuit seeks to recover damages for all persons and entities that purchased or sold Cepton common stock during the Class Period [1] - Investors have until December 8, 2025, to request to be appointed as Lead Plaintiff for the class [2] Group 2: Company Background - Cepton is an electronics company focused on high-performance lidar technologies for the Automotive and Smart Infrastructure markets, offering various lidar systems and software [3] - Koito Manufacturing Co., Ltd. invested $200 million in Cepton, acquiring 30.1% of voting power and two board seats as of July 2023 [4] Group 3: Merger and Allegations - In July 2024, Cepton accepted Koito's bid to acquire all outstanding capital stock for $3.17 per share, which closed on January 7, 2025 [5] - The lawsuit alleges that Cepton's Board failed to disclose a credible third-party bid valuing the company at more than double the Koito Acquisition price, depriving shareholders of meaningful consideration [5][7] - The Amended Complaint claims that the acquisition price was unreasonable and that the Board concealed critical facts in their communications with shareholders [7]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Snap Inc. securities between April 29, 2025, and August 5, 2025, about the October 20, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Snap securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by October 20, 2025 [2]. - The lawsuit alleges that Snap's management misrepresented the company's advertising revenue and growth potential, leading to investor losses when the true situation was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3].

, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against C3.ai, Inc. (NYSE: AI) ("C3.ai" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 26, 2025 through August 8, 2025 (the "Class Period"), Investor Deadline: Investors who purchased or acquired C3.ai securities during the Class Period may, no later than October 21, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Palantir Technologies Inc. ("Palantir†or the "Company†) (NASDAQ: PLTR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PALANTIR TECHNOLOGIES INC. (PLTR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Ha. ...

Core Viewpoint - The KinderCare Learning Companies, Inc. is facing a class action lawsuit related to its October 2024 IPO, alleging violations of the Securities Act of 1933 due to misleading statements regarding the quality of care provided at its facilities and undisclosed risks [1][3]. Summary by Sections Class Action Lawsuit - Investors who purchased KinderCare common stock during or traceable to the IPO have until October 14, 2025, to seek lead plaintiff status in the class action lawsuit [1]. - The lawsuit is titled Gollapalli v. KinderCare Learning Companies, Inc. and includes allegations against KinderCare's executives, directors, and IPO underwriters [1][2]. IPO Details - KinderCare sold over 27 million shares at $24 per share during the IPO, raising a total of $648 million in gross proceeds [2]. Allegations Against KinderCare - The lawsuit claims that the IPO registration statement was false or misleading, failing to disclose incidents of child abuse and neglect at KinderCare facilities [3]. - It is alleged that KinderCare did not provide the "highest quality care possible" and failed to meet basic industry standards, exposing the company to significant undisclosed risks [3]. Stock Performance - Following the IPO, KinderCare's stock price has significantly declined, reaching lows near $9 per share [4]. Legal Representation - The plaintiffs are represented by Robbins Geller, a law firm with extensive experience in prosecuting investor class actions, particularly those involving financial fraud [4][6].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was monitoring utilization patterns to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, Molina adjusted its full-year 2025 earnings expectation to no less than $19.00 per diluted share, citing a challenging medical cost trend environment [4]. - The stock price fell by $32.03 per share, or 16.8%, from $190.25 on July 23, 2025, to $158.22 on July 24, 2025, in response to these announcements [4].

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following disappointing financial results and claims of overstated demand for its Prestige fragrances [1][2][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products [2]. - Prestige fragrances represent 60% of Coty's revenues, highlighting the significance of this segment to the company's financial health [2]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as weaknesses in U.S. execution, retailer inventory buildup, and challenges from previous fiscal year innovations [3]. - The company's stock price fell by $1.05, a decline of over 21%, from $4.86 to $3.81 per share following the announcement of these results [3]. Group 3: Market Dynamics - The investigation stems from claims that Coty misrepresented the demand for its products, as retailers were reportedly overstocked due to a decline in actual demand [2]. - Factors contributing to the slowdown in cosmetics sales included value-seeking consumer behavior, fatigue with innovation, and specific U.S. market challenges such as in-store theft measures and immigration policy changes [3].